An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension

The emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutants and breakthrough infections despite available coronavirus disease 2019 (COVID-19) vaccines calls for antiviral therapeutics. The application of soluble angiotensin converting enzyme 2 (ACE2) as a SARS-CoV-2 dec...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuchs, Elisabeth, Rudnik-Jansen, Imke, Dinesen, Anders, Selnihhin, Denis, Mandrup, Ole Aalund, Thiam, Kader, Kjems, Jørgen, Pedersen, Finn Skou, Howard, Kenneth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of Acta Materialia Inc. 2022
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508356/
https://www.ncbi.nlm.nih.gov/pubmed/36162760
http://dx.doi.org/10.1016/j.actbio.2022.09.048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508356/
https://www.ncbi.nlm.nih.gov/pubmed/36162760
http://dx.doi.org/10.1016/j.actbio.2022.09.048

Ejemplares similares